Ekaterina D. Mironova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ekaterina D. Mironova has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Mikhail Alekseevich Osadchuk
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
9 shared publications - Andrey A. Svistunov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
3 shared publications - Inna N. Vasilieva
N.V. Sklifosovsky Institute of Clinical Medicine, Department of Polyclinic Therapy, I.M. Sechenov First Moscow State Medical University, 119435 Moscow, Russia
3 shared publications - Maksim M. Osadchuk
City Polyclinic №52
3 shared publications - Yulia Sergeevna Krylova
Department of Pathology, Pavlov First Saint-Petersburg State Medical University, L’va Tolstogo Street 6-8, 197022 Saint-Petersburg, Russia
3 shared publications - Igor Veniaminovich Maev
Department of Internal Disease Propaedeutics and Gastroenterology, Russian University of Medicine, 127473 Moscow, Russia
2 shared publications
Latest Publications
- Open Access
- 7 March 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (2) , 110-114
Chronic gastroduodenitis, associated and not associated with Helicobacter pylori infection, and its relationship with functional intestinal pathology depending on the content of fecal calprotectin
Background. In recent years, the role of chronic gastroduodenitis in the occurrence of functional intestinal diseases within the framework of the crossover syndrome, which occurs against the background of minimal inflammation in the stomach and intestines associated with Helicobacter pylori infection, has become increasingly relevant. Aim. To determine the relationship of chronic gastroduodenitis, associated and not associated with H. pylori infection, with the level of fecal calprotectin (FC) and clinical symptoms of functional intestinal disorders. Materials and methods. The study included 158 patients with chronic gastroduodenitis: group 1 (80 patients with gastroduodenitis associated with H. pylori infection in the stomach) and group 2 (76 patients without H. pylori infection). All patients had clinical symptoms of the gastrointestinal tract for at least a year. The patients underwent esophagoduodenoscopy and colonoscopy. Verification of H. pylori was based on data from histiobacterioscopy of impression smears from the mucous membrane of the antrum of the stomach. FC content was determined using an express analyzer. Results. Patients of the first group significantly more often complained of pain, a burning sensation and fullness after eating in the epigastric region, nausea, belching, heartburn, flatulence, pain along the large intestine, a feeling of incomplete evacuation after defecation compared to the group without H. pylori infection. At the same time, in patients with H. pylori infection, FC values were most often determined in the range from 50 to 200 μg/g – in 28.75%, and in patients not infected with H. pylori infection – 13.15% (p 0.05). Conclusion. The studies conducted indicate the presence of a statistically significant relationship between chronic gastroduodenitis and functional intestinal disorders, which can be bidirectional in nature, the basis of which is minimal inflammation caused by the presence of H. pylori infection and increased production of FC.
- 7 March 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (2) , 110-114
Open AccessChronic gastroduodenitis, associated and not associated with Helicobacter pylori infection, and its relationship with functional intestinal pathology depending on the content of fecal calprotectin
Background. In recent years, the role of chronic gastroduodenitis in the occurrence of functional intestinal diseases within the framework of the crossover syndrome, which occurs against the background of minimal inflammation in the stomach and intestines associated with Helicobacter pylori infection, has become increasingly relevant. Aim. To determine the relationship of chronic gastroduodenitis, associated and not associated with H. pylori infection, with the level of fecal calprotectin (FC) and clinical symptoms of functional intestinal disorders. Materials and methods. The study included 158 patients with chronic gastroduodenitis: group 1 (80 patients with gastroduodenitis associated with H. pylori infection in the stomach) and group 2 (76 patients without H. pylori infection). All patients had clinical symptoms of the gastrointestinal tract for at least a year. The patients underwent esophagoduodenoscopy and colonoscopy. Verification of H. pylori was based on data from histiobacterioscopy of impression smears from the mucous membrane of the antrum of the stomach. FC content was determined using an express analyzer. Results. Patients of the first group significantly more often complained of pain, a burning sensation and fullness after eating in the epigastric region, nausea, belching, heartburn, flatulence, pain along the large intestine, a feeling of incomplete evacuation after defecation compared to the group without H. pylori infection. At the same time, in patients with H. pylori infection, FC values were most often determined in the range from 50 to 200 μg/g – in 28.75%, and in patients not infected with H. pylori infection – 13.15% (p 0.05). Conclusion. The studies conducted indicate the presence of a statistically significant relationship between chronic gastroduodenitis and functional intestinal disorders, which can be bidirectional in nature, the basis of which is minimal inflammation caused by the presence of H. pylori infection and increased production of FC.
- Open Access
- 1 January 2025
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 14 (3)
Digital medicine and artificial intelligence: present and future
Цифровая медицина и искусственный интеллект: настоящее и будущее
- 1 January 2025
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 14 (3)
Open AccessDigital medicine and artificial intelligence: present and future
Цифровая медицина и искусственный интеллект: настоящее и будущее
- Open Access
- 30 September 2024
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in University therapeutic journal
- Vol. 6 (2) , 58-65
FECAL CALPROTECTIN AS A DIAGNOSTIC MARKER OF COLORECTAL CANCER IN PERSONS WITH DIVERTICULAR DISEASE OF THE COLON
Введение. Дивертикулярная болезнь толстой кишки (ДБТК) и колоректальный рак (КРР) являются двумя наиболее распространенными желудочно-кишечными заболеваниями, обеспечивающими высокую нагрузку на систему здравоохранения. Проведение скрининга КРР при ДБТК связано со значительными материальными затратами на проведение колоноскопии с последующим взятием биопсии из слизистой оболочки кишечника. Цель исследования. Определить прогностическую значимость фекального кальпротектина(ФК), в плане возможного скрининга, дивертикулярной болезни толстой кишки (ДБТК) и при ее сочетании с колоректальным раком (КРР). Материалы и методы. В исследованиевключено 60 пациентов с ДБТК старше 40 лет, которые были распределены на 2 группы: в первую группу вошли 30 пациентов с ДБТК; во вторую группу вошли 30 пациентов сДБТК и КРР (I или II стадии). Группу сравнения составили 25 практически здоровых человек, прошедших плановую диспансеризацию. Все пациенты обследованы в соответствии сцелью и задачами настоящей работы по единой программе, включающей рутинные лабораторные и инструментальные (колоноскопия и ультразвуковое исследование органов брюшной полости) данные. Включенным в обследование пациентам проводился анализ кала на скрытую кровь и определение уровня ФК. Результаты. У пациентов с ДБТК положительная реакция кала на скрытую кровь обнаружена у 3,3%, а при ее сочетании с КРР — у 30% (p <0,05). У пациентов с ДБТК наиболее часто определялись значения ФК в диапазоне от 50 до 200 мкг/г — у 33,3%, а у пациентов с ДБТК в сочетании с КРР — у 60% (p <0,05). В группе пациентов с ДБТК в сочетании с КРР уровень ФК в среднем составил 83,53 мкг/г, а в группе с ДБТК — 67,24 мкг/г, при значениях данного показателя в группе практически здоровых пациентов 31,12 мкг/г (p <0,05). Сравнение между собой больных с ДБТК и КРР показало, что у пациентов с ДБТК в сочетании с КРР определялись более высокие показатели ФК (p <0,05). Выводы. ФК может использоваться в качестве маркера для скрининга КРР и ДБТК. Introduction. Diverticular disease of the colon (DD) and colorectal cancer (CRC) are the two most common gastrointestinal diseases that place a high burden on the healthcare system. Screening for CRC in DBTC is associated with significant material costs for colonoscopy followed by biopsy from the intestinal mucosa. To determine the prognostic significance of fecal calprotectin (FC) in patients with (DD) and in its combination with CRC. The aim is to determine the prognostic significance of fecal calprotectin (FC) in patients with diverticular disease of the colon (DD) and in its combination with colorectal cancer (CRC). Materials and methods. The study included 60 patients over 40 years of age with DD, who were divided into 2 groups: the first group included 30 patients with DD; the second group included 30 patients with DD and CRC (stages I or II). The comparison group consisted of 25 practically healthy people who underwent a routine medical examination. All patients were examined in accordance with the purpose and objectives of this work according to a single program, including routine laboratory and instrumental (colonoscopy and ultrasound examination of the abdominal organs) data. All patients underwent stool testing for occult blood and FC levels. Results. In patients with DD, a positive fecal occult blood reaction was found in 3.3%, and when combined with CRC, in 30% (p <0.05). In patients with DD, FC values were most often determined in the range from 50 to 200 μg/g (which may indicate an organic disease in remission) — in 33.3%, and in patients with DD in combination with CRC — in 60% (p <0.05). In patients with DD, the level of FC was significantly higher than in representatives of the group of practically healthy patients (p <0.05). Thus, in the group with DD in combination with CRC, the FA level was 83.53 μg/g, in the group with DD 67.24 μg/g, while the values of this indicator in the group of practically healthy patients were 31.12 μg/g (p <0.05). A comparison between patients with DD and CRC showed that patients with DD in combination with CRC had higher FC values (p <0.05). Conclusions. FC is a prognostically valuable marker for the detection of CRC in patients with DD.
- 30 September 2024
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in University therapeutic journal
- Vol. 6 (2) , 58-65
Open AccessFECAL CALPROTECTIN AS A DIAGNOSTIC MARKER OF COLORECTAL CANCER IN PERSONS WITH DIVERTICULAR DISEASE OF THE COLON
Введение. Дивертикулярная болезнь толстой кишки (ДБТК) и колоректальный рак (КРР) являются двумя наиболее распространенными желудочно-кишечными заболеваниями, обеспечивающими высокую нагрузку на систему здравоохранения. Проведение скрининга КРР при ДБТК связано со значительными материальными затратами на проведение колоноскопии с последующим взятием биопсии из слизистой оболочки кишечника. Цель исследования. Определить прогностическую значимость фекального кальпротектина(ФК), в плане возможного скрининга, дивертикулярной болезни толстой кишки (ДБТК) и при ее сочетании с колоректальным раком (КРР). Материалы и методы. В исследованиевключено 60 пациентов с ДБТК старше 40 лет, которые были распределены на 2 группы: в первую группу вошли 30 пациентов с ДБТК; во вторую группу вошли 30 пациентов сДБТК и КРР (I или II стадии). Группу сравнения составили 25 практически здоровых человек, прошедших плановую диспансеризацию. Все пациенты обследованы в соответствии сцелью и задачами настоящей работы по единой программе, включающей рутинные лабораторные и инструментальные (колоноскопия и ультразвуковое исследование органов брюшной полости) данные. Включенным в обследование пациентам проводился анализ кала на скрытую кровь и определение уровня ФК. Результаты. У пациентов с ДБТК положительная реакция кала на скрытую кровь обнаружена у 3,3%, а при ее сочетании с КРР — у 30% (p <0,05). У пациентов с ДБТК наиболее часто определялись значения ФК в диапазоне от 50 до 200 мкг/г — у 33,3%, а у пациентов с ДБТК в сочетании с КРР — у 60% (p <0,05). В группе пациентов с ДБТК в сочетании с КРР уровень ФК в среднем составил 83,53 мкг/г, а в группе с ДБТК — 67,24 мкг/г, при значениях данного показателя в группе практически здоровых пациентов 31,12 мкг/г (p <0,05). Сравнение между собой больных с ДБТК и КРР показало, что у пациентов с ДБТК в сочетании с КРР определялись более высокие показатели ФК (p <0,05). Выводы. ФК может использоваться в качестве маркера для скрининга КРР и ДБТК. Introduction. Diverticular disease of the colon (DD) and colorectal cancer (CRC) are the two most common gastrointestinal diseases that place a high burden on the healthcare system. Screening for CRC in DBTC is associated with significant material costs for colonoscopy followed by biopsy from the intestinal mucosa. To determine the prognostic significance of fecal calprotectin (FC) in patients with (DD) and in its combination with CRC. The aim is to determine the prognostic significance of fecal calprotectin (FC) in patients with diverticular disease of the colon (DD) and in its combination with colorectal cancer (CRC). Materials and methods. The study included 60 patients over 40 years of age with DD, who were divided into 2 groups: the first group included 30 patients with DD; the second group included 30 patients with DD and CRC (stages I or II). The comparison group consisted of 25 practically healthy people who underwent a routine medical examination. All patients were examined in accordance with the purpose and objectives of this work according to a single program, including routine laboratory and instrumental (colonoscopy and ultrasound examination of the abdominal organs) data. All patients underwent stool testing for occult blood and FC levels. Results. In patients with DD, a positive fecal occult blood reaction was found in 3.3%, and when combined with CRC, in 30% (p <0.05). In patients with DD, FC values were most often determined in the range from 50 to 200 μg/g (which may indicate an organic disease in remission) — in 33.3%, and in patients with DD in combination with CRC — in 60% (p <0.05). In patients with DD, the level of FC was significantly higher than in representatives of the group of practically healthy patients (p <0.05). Thus, in the group with DD in combination with CRC, the FA level was 83.53 μg/g, in the group with DD 67.24 μg/g, while the values of this indicator in the group of practically healthy patients were 31.12 μg/g (p <0.05). A comparison between patients with DD and CRC showed that patients with DD in combination with CRC had higher FC values (p <0.05). Conclusions. FC is a prognostically valuable marker for the detection of CRC in patients with DD.
- Open Access
- 14 September 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (8) , 732-738
Clinical, endoscopic, laboratory and immunomorphological parameters in predicting the occurrence of colorectal cancer in patients with diverticular disease of the colon
Aim. To define the role of clinical, endoscopic, laboratory and immunomorphological parameters in predicting the occurrence and course of colorectal cancer (CRC) in patients with diverticular disease of the colon (DDC). Materials and methods. One hundred and seventy five people with DDC were examined, divided into 3 groups: group 1 – 85 patients with DDC; group 2 – 45 with DDC in combination with adenomatous polyps (AP); 3rd group – 45 with DDC with established CRC (I or II stage). The control group consisted of 30 practically healthy people. Patients and healthy people were examined according to a single program: clinical, laboratory, instrumental data and immunomorphological research methods [use of primary antibodies to p53 (mAb clone DO-7 product no. PA0057, Leica Biosystems, Leica Bond III) and Ki-67 (Ab16667, Abcam, UK)]. Results. Among the main complaints in patients with DDC and CRC, constipation was more common than in patients with DDC and DDC with AP (p0.05). In patients with DDC and colorectal neoplasia, a positive reaction to occult blood in the feces was more often verified, compared with the group with DDC (p0.05). Higher levels of glucose and cholesterol in blood plasma, as well as body mass index were found in patients with DDC with AP and CRC, compared with the DDC group (p0.05). A higher level of expression of Ki-67 and p53 was found in patients with DDC combined with AP and CRC, compared with patients with DDC without colorectal neoplasia (p0.05). At the same time, in patients with DDC with CRC, the expression level of Ki-67 and p53 was higher than in patients with DDC with AP (p0.05) Conclusion. In patients with DDC combined with AP and CRC, higher levels of glucose, plasma cholesterol, as well as body mass index were observed compared to the group of patients with DDC alone (p0.05). Of note, the results of the determination of Ki-67 and p53 in the mucous membrane of the colon should be considered important prognostic markers for the development of CRC in patients with DDC.
- 14 September 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (8) , 732-738
Open AccessClinical, endoscopic, laboratory and immunomorphological parameters in predicting the occurrence of colorectal cancer in patients with diverticular disease of the colon
Aim. To define the role of clinical, endoscopic, laboratory and immunomorphological parameters in predicting the occurrence and course of colorectal cancer (CRC) in patients with diverticular disease of the colon (DDC). Materials and methods. One hundred and seventy five people with DDC were examined, divided into 3 groups: group 1 – 85 patients with DDC; group 2 – 45 with DDC in combination with adenomatous polyps (AP); 3rd group – 45 with DDC with established CRC (I or II stage). The control group consisted of 30 practically healthy people. Patients and healthy people were examined according to a single program: clinical, laboratory, instrumental data and immunomorphological research methods [use of primary antibodies to p53 (mAb clone DO-7 product no. PA0057, Leica Biosystems, Leica Bond III) and Ki-67 (Ab16667, Abcam, UK)]. Results. Among the main complaints in patients with DDC and CRC, constipation was more common than in patients with DDC and DDC with AP (p0.05). In patients with DDC and colorectal neoplasia, a positive reaction to occult blood in the feces was more often verified, compared with the group with DDC (p0.05). Higher levels of glucose and cholesterol in blood plasma, as well as body mass index were found in patients with DDC with AP and CRC, compared with the DDC group (p0.05). A higher level of expression of Ki-67 and p53 was found in patients with DDC combined with AP and CRC, compared with patients with DDC without colorectal neoplasia (p0.05). At the same time, in patients with DDC with CRC, the expression level of Ki-67 and p53 was higher than in patients with DDC with AP (p0.05) Conclusion. In patients with DDC combined with AP and CRC, higher levels of glucose, plasma cholesterol, as well as body mass index were observed compared to the group of patients with DDC alone (p0.05). Of note, the results of the determination of Ki-67 and p53 in the mucous membrane of the colon should be considered important prognostic markers for the development of CRC in patients with DDC.
- Open Access
- 10 September 2024
- Published by Joint Editorial Office of the Ministry of Internal Affairs of Russia in Medical Bulletin of the Ministry of Internal Affairs
- Vol. 2024 (4) , 49-56
VASCULAR AGING SYNDROME IN CASE OF METABOLIC DISORDERS AND ARTERIAL HYPERTENSION. VASOPROTECTIVE ROLE OF COMBINED ANTIHYPERTENSIVE THERAPY
Metabolic disorders contribute to the premature development of arterial stiffness and form phenotypic modulations of heart and vessel remodeling. Adverse effect of metabolic disorders on hemodynamics of the cardiovascular system has been detected. Fixed combination of perindopril and amlodipine determined positive effect on the dynamics of vascular stiffness parameters in patients with arterial hypertension: vascular stiffness index, maximal arterial pressure increase rate dP/dtmax, central pressure in the aorta SYSao. At the same time the issue of duration of the treatment in the framework of angioprotection needs further study and detailed analysis.
- 10 September 2024
- Published by Joint Editorial Office of the Ministry of Internal Affairs of Russia in Medical Bulletin of the Ministry of Internal Affairs
- Vol. 2024 (4) , 49-56
Open AccessVASCULAR AGING SYNDROME IN CASE OF METABOLIC DISORDERS AND ARTERIAL HYPERTENSION. VASOPROTECTIVE ROLE OF COMBINED ANTIHYPERTENSIVE THERAPY
Metabolic disorders contribute to the premature development of arterial stiffness and form phenotypic modulations of heart and vessel remodeling. Adverse effect of metabolic disorders on hemodynamics of the cardiovascular system has been detected. Fixed combination of perindopril and amlodipine determined positive effect on the dynamics of vascular stiffness parameters in patients with arterial hypertension: vascular stiffness index, maximal arterial pressure increase rate dP/dtmax, central pressure in the aorta SYSao. At the same time the issue of duration of the treatment in the framework of angioprotection needs further study and detailed analysis.
- Open Access
- 30 March 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (2) , 97-101
Expression of motilin and vasoactive intestinal peptide in diverticular disease of the colon
Aim. To determine the role of the expression of motilin and vasoactive intestinal peptide (VIP) in diverticular disease of the large intestine (DD). Materials and methods. Examined 45 patients with DD. The comparison group consisted of 30 practically healthy people. Patients and healthy people were examined according to a single program, including clinical, instrumental (colonoscopy and ultrasound examination of the abdominal cavity and), laboratory (blood glucose, cholesterol, alanine aminotransferase and aspartate aminotransferase) and immunomorphological research methods – use of primary antibodies to motilin (PA5-76926, Invitrogen, USA) and VIP (Ab22736, 1:800, Abcam, UK). Results. For DD, clinical symptoms are characteristic, mainly fit into the manifestations of functional disorders (constipation, pain along the colon, bloating and increased gas formation). In patients with DD, an increase in body mass index, cholesterol and glucose levels was found. In this category of patients, examinations often verify diabetes mellitus (40%), arterial hypertension (64.4%), cholelithiasis (44.4%), non-alcoholic fatty liver disease (55.5%), gastroesophageal reflux disease (60%). In the group of patients with DD, a significant decrease in the expression of VIP and motilin in the mucous membrane of the large intestine was recorded compared with the group of healthy people (17.31 vs 34.67; p0.05 and 64.42 vs 76.50; p0.05 respectively). Conclusion. The obtained results give grounds to conclude that a decrease in the expression of VIP and motilin in the mucosa of the sigmoid colon is accompanied by hypotension of the colon, which directly and indirectly leads to a violation of the regeneration of the mucosa, which leads to the manifestation of DD.
- 30 March 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (2) , 97-101
Open AccessExpression of motilin and vasoactive intestinal peptide in diverticular disease of the colon
Aim. To determine the role of the expression of motilin and vasoactive intestinal peptide (VIP) in diverticular disease of the large intestine (DD). Materials and methods. Examined 45 patients with DD. The comparison group consisted of 30 practically healthy people. Patients and healthy people were examined according to a single program, including clinical, instrumental (colonoscopy and ultrasound examination of the abdominal cavity and), laboratory (blood glucose, cholesterol, alanine aminotransferase and aspartate aminotransferase) and immunomorphological research methods – use of primary antibodies to motilin (PA5-76926, Invitrogen, USA) and VIP (Ab22736, 1:800, Abcam, UK). Results. For DD, clinical symptoms are characteristic, mainly fit into the manifestations of functional disorders (constipation, pain along the colon, bloating and increased gas formation). In patients with DD, an increase in body mass index, cholesterol and glucose levels was found. In this category of patients, examinations often verify diabetes mellitus (40%), arterial hypertension (64.4%), cholelithiasis (44.4%), non-alcoholic fatty liver disease (55.5%), gastroesophageal reflux disease (60%). In the group of patients with DD, a significant decrease in the expression of VIP and motilin in the mucous membrane of the large intestine was recorded compared with the group of healthy people (17.31 vs 34.67; p0.05 and 64.42 vs 76.50; p0.05 respectively). Conclusion. The obtained results give grounds to conclude that a decrease in the expression of VIP and motilin in the mucosa of the sigmoid colon is accompanied by hypotension of the colon, which directly and indirectly leads to a violation of the regeneration of the mucosa, which leads to the manifestation of DD.
- Open Access
- 17 January 2024
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 9,p. 177-185
Antibiotics: the triumph of civilization and its other side
The synthesis of antibacterial drugs and their subsequent use in clinical practice contributed to saving a huge number of people’s lives in the global space. At the same time, they can cause significant harm, including Clostridium difficile infections, in the formation of antibiotic resistance and changes in the human microbiome, the consequences of which have yet to be assessed. Antibiotic management programs are becoming more and more commonplace in modern clinical practice, requiring extensive knowledge based on clinical, genomic and laboratory data. Increasing evidence suggests a role for antibiotics in the manifestation of allergic, inflammatory, metabolic, and functional diseases. On the other hand, there is more and more data on the role of antimicrobial drugs in cancer prevention and treatment of viral diseases.
- 17 January 2024
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 9,p. 177-185
Open AccessAntibiotics: the triumph of civilization and its other side
The synthesis of antibacterial drugs and their subsequent use in clinical practice contributed to saving a huge number of people’s lives in the global space. At the same time, they can cause significant harm, including Clostridium difficile infections, in the formation of antibiotic resistance and changes in the human microbiome, the consequences of which have yet to be assessed. Antibiotic management programs are becoming more and more commonplace in modern clinical practice, requiring extensive knowledge based on clinical, genomic and laboratory data. Increasing evidence suggests a role for antibiotics in the manifestation of allergic, inflammatory, metabolic, and functional diseases. On the other hand, there is more and more data on the role of antimicrobial drugs in cancer prevention and treatment of viral diseases.
- Open Access
- 17 January 2024
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 9,p. 68-74
Expression of motilin and vasoactive intestinal peptide in the mucosa of the sigmoid colon in patients with diverticular disease of the large intestine and irritable bowel syndrome
Экспрессия мотилина и вазоактивного кишечного пептида в слизистой оболочке сигмовидной кишки у больных с дивертикулярной болезнью толстого кишечника и синдромом раздраженного кишечника
- 17 January 2024
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 9,p. 68-74
Open AccessExpression of motilin and vasoactive intestinal peptide in the mucosa of the sigmoid colon in patients with diverticular disease of the large intestine and irritable bowel syndrome
Экспрессия мотилина и вазоактивного кишечного пептида в слизистой оболочке сигмовидной кишки у больных с дивертикулярной болезнью толстого кишечника и синдромом раздраженного кишечника
- 23 April 2023
- Published by Media Sphere Publishing Group in Russian Journal of Evidence-Based Gastroenterology
- Vol. 12 (4)
The influence of rosuvastatin on the efficacy of standard triple eradication therapy in patients with gallstone disease and Helicobacter pylori infection
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить влияние розувастатина (гиполипидемического препарата) на эффективность литолитической и эрадикационной терапии у пациентов с желчнокаменной болезнью (ЖКБ). МАТЕРИАЛ И МЕТОДЫ В исследовании участвовали 122 пациента с конкрементами диаметром Helicobacter pylori. При обнаружении H. pylori назначалась тройная эрадикационная терапия в течение 14 дней с оценкой результатов через 4 недели. Всем испытуемым до лечения, спустя 3, 6, 9 и 12 мес проводили ультразвуковое исследование брюшной полости. До лечения, через 6 и 12 мес определяли показатели липидограммы в сыворотке крови. РЕЗУЛЬТАТЫ Наибольшая инфицированность H. pylori зафиксирована у пациентов с ГХ 1-й и 2-й групп: 66,6 и 67,5% соответственно. Наибольший уровень элиминации H. pylori достигнут у пациентов 2-й группы — 96,2%, наименьший у пациентов 1-й группы — 78,5% (pH. pylori целесообразно назначать розувастатин в качестве одного из компонентов литолитической и/или эрадикационной терапии.
- 23 April 2023
- Published by Media Sphere Publishing Group in Russian Journal of Evidence-Based Gastroenterology
- Vol. 12 (4)
The influence of rosuvastatin on the efficacy of standard triple eradication therapy in patients with gallstone disease and Helicobacter pylori infection
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить влияние розувастатина (гиполипидемического препарата) на эффективность литолитической и эрадикационной терапии у пациентов с желчнокаменной болезнью (ЖКБ). МАТЕРИАЛ И МЕТОДЫ В исследовании участвовали 122 пациента с конкрементами диаметром Helicobacter pylori. При обнаружении H. pylori назначалась тройная эрадикационная терапия в течение 14 дней с оценкой результатов через 4 недели. Всем испытуемым до лечения, спустя 3, 6, 9 и 12 мес проводили ультразвуковое исследование брюшной полости. До лечения, через 6 и 12 мес определяли показатели липидограммы в сыворотке крови. РЕЗУЛЬТАТЫ Наибольшая инфицированность H. pylori зафиксирована у пациентов с ГХ 1-й и 2-й групп: 66,6 и 67,5% соответственно. Наибольший уровень элиминации H. pylori достигнут у пациентов 2-й группы — 96,2%, наименьший у пациентов 1-й группы — 78,5% (pH. pylori целесообразно назначать розувастатин в качестве одного из компонентов литолитической и/или эрадикационной терапии.
- 26 May 2022
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 77 (2) , 79-86
The Role of Endocrine Cells of the Colon, Secreting Vasoactive Intestinal Polypeptide, Somatostatin and Motilin, in Irritable Bowel Syndrome, Occurring with Diarrhea and Constipation
Background. Disorders in the production of neuroendocrine peptides in the digestive tract can cause changes in, intestinal motility and the formation of visceral hypersensitivity, characteristic of patients with irritable bowel syndrome (IBS). From this standpoint, of particular interest is the study of the role of a number of major endocrine cells (EC) of the colon, secreting motilin, vasoactive intestinal polypeptide, and somatostatin, in IBS. Aims to evaluate the density of ECs with different hormonal activities that secrete motilin, vasoactive intestinal polypeptide and somatostatin in the mucosa of the sigmoid colon in patients with IBS that occurs with constipation and diarrhea. Materials and methods. 85 patients with IBS were examined. The first group included 44 patients with diarrhea (IBSd), the second group included 41 patients with constipation (IBSc). The comparison group consisted of 36 practically healthy people. The diagnosis of IBS was based on the Rome IV criteria. Patients and healthy people were examined according to a single program, including clinical, instrumental (colonoscopy, ultrasound examination of the abdominal organs), laboratory (clinical blood test, feces for calprotectin and antibodies to gliadin in the presence of diarrhea), morphological and immunohistochemical methods. Results. The clinical picture of IBS corresponded to the classical manifestations of this pathology. Among patients with IBSc, there was a more frequent feeling of incomplete emptying of the intestine after defecation, compared with patients with IBSd (p 0.05). Among patients with IBSd, there was a statistically significant increase in the number of ECs producing motilin and vasoactive intestinal polypeptide, as well as a lower density of ECs secreting somatostatin, compared with the control group (p 0.05). In the IBSc group, there was a decrease in the number of ECs producing motilin, vasoactive intestinal polypeptide and an increase in the number of ECs producing somatostatin, compared with the control group (p 0.05). Conclusions. An increase in the number of cells producing motilin, vasoactive intestinal polypeptide and a decrease in the number of cells observed for the production of somatostatin in the mucosa of the sigmoid colon is characteristic of the manifestation of IBSd. At the same time, an increase in ECs secreting motilin, vasoactive intestinal polypeptide and an increase in cellular elements producing somatostatin reveals manifestations of IBSс.
- 26 May 2022
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 77 (2) , 79-86
The Role of Endocrine Cells of the Colon, Secreting Vasoactive Intestinal Polypeptide, Somatostatin and Motilin, in Irritable Bowel Syndrome, Occurring with Diarrhea and Constipation
Background. Disorders in the production of neuroendocrine peptides in the digestive tract can cause changes in, intestinal motility and the formation of visceral hypersensitivity, characteristic of patients with irritable bowel syndrome (IBS). From this standpoint, of particular interest is the study of the role of a number of major endocrine cells (EC) of the colon, secreting motilin, vasoactive intestinal polypeptide, and somatostatin, in IBS. Aims to evaluate the density of ECs with different hormonal activities that secrete motilin, vasoactive intestinal polypeptide and somatostatin in the mucosa of the sigmoid colon in patients with IBS that occurs with constipation and diarrhea. Materials and methods. 85 patients with IBS were examined. The first group included 44 patients with diarrhea (IBSd), the second group included 41 patients with constipation (IBSc). The comparison group consisted of 36 practically healthy people. The diagnosis of IBS was based on the Rome IV criteria. Patients and healthy people were examined according to a single program, including clinical, instrumental (colonoscopy, ultrasound examination of the abdominal organs), laboratory (clinical blood test, feces for calprotectin and antibodies to gliadin in the presence of diarrhea), morphological and immunohistochemical methods. Results. The clinical picture of IBS corresponded to the classical manifestations of this pathology. Among patients with IBSc, there was a more frequent feeling of incomplete emptying of the intestine after defecation, compared with patients with IBSd (p 0.05). Among patients with IBSd, there was a statistically significant increase in the number of ECs producing motilin and vasoactive intestinal polypeptide, as well as a lower density of ECs secreting somatostatin, compared with the control group (p 0.05). In the IBSc group, there was a decrease in the number of ECs producing motilin, vasoactive intestinal polypeptide and an increase in the number of ECs producing somatostatin, compared with the control group (p 0.05). Conclusions. An increase in the number of cells producing motilin, vasoactive intestinal polypeptide and a decrease in the number of cells observed for the production of somatostatin in the mucosa of the sigmoid colon is characteristic of the manifestation of IBSd. At the same time, an increase in ECs secreting motilin, vasoactive intestinal polypeptide and an increase in cellular elements producing somatostatin reveals manifestations of IBSс.